Introduction
Evidence on infant vaccination after maternal biologic exposure in inflammatory bowel disease (IBD) remains limited, particularly for live-attenuated vaccines and breastfeeding exposure. We evaluated vaccine safety in children born to mothers with IBD included in a prospective national registry and specifically assessed vaccine-related serious adverse events (SAEs) after prenatal and/or breastfeeding exposure to biologics.
Aims & Methods
This multicentre prospective observational cohort study was conducted within the Spanish DUMBO registry of GETECCU. Infants born to mothers with IBD were followed prospectively, and maternal treatment exposure during pregnancy and breastfeeding, infant vaccination data, and SAEs potentially related to vaccination were systematically collected at protocol-defined visits and confirmed by medical record review. The main outcome was investigator-reported SAE possibly attributable to vaccination. Vaccination uptake for rotavirus, measles–mumps–rubella (MMR), and varicella was also assessed in infants exposed to biologics during pregnancy or breastfeeding. Given the expected rarity of vaccine-related SAEs, the analysis was primarily descriptive.
Results
A total of 1,009 children were included. Median gestational age at birth was 39.6 weeks and prematurity occurred in 72/1,007 children (7.2%). During pregnancy, 437 infants were exposed to biologics, including anti-tumour necrosis factor (TNF) agents in 304, ustekinumab in 97, vedolizumab in 33, and risankizumab or mirikizumab in 3. During breastfeeding, 282 infants were exposed to biologics, including anti-TNF agents in 199, ustekinumab in 53, vedolizumab in 26, and risankizumab in 4. Among infants exposed to biologics during pregnancy, rotavirus first and second doses were administered to 209 (49%) and 203 (48%), while MMR and varicella first doses were given to 363 (85%) and 323 (76%), respectively. Among infants exposed to biologics during breastfeeding, rotavirus first and second doses were administered to 132 (47%) and 129 (46%), while MMR and varicella first doses were given to 243 (87%) and 216 (78%), respectively. Among children who completed the corresponding visits within the protocol-defined time window, age-appropriate vaccination coverage was high: rotavirus first dose was administered to 198/388 (51%) and 128/263 (49%) of biologic-exposed infants during pregnancy and breastfeeding, respectively, whereas MMR and varicella coverage reached 99% and 97% in both exposure groups. Overall, only 3/1,009 children (0.3%) experienced an SAE considered possibly related to vaccination; all required hospital admission, none had long-term sequelae, and only one event occurred after a live vaccine (rotavirus), in an infant not exposed to biologics.
Table: patients with serious adverse events (SAEs) possibly related to vaccination
| | Patient 1 | Patient 2 | Patient 3 |
| Age and sex | 2 months, male | 2 months, male | 2 months, female |
| Type of feeding | Mixed feeding | Mixed feeding | Breastfeeding |
| Type of vaccine | - Hexavalent vaccine - Pneumococcal vaccine - Respiratory Syncytial Virus vaccine | - Hexavalent vaccine - Pneumococcal vaccine - Respiratory Syncytial Virus vaccine | - Hexavalent vaccine - Pneumococcal vaccine - Rotavirus |
| Type of SAE and treatment | Fever: intravenous cefotaxime followed by oral amoxicillin at discharge | Paroxysmal event and fever: no treatment | Paroxysmal event (infantile myoclonus): no treatment |
| Mother’s diagnosis and treatment | Ulcerative colitis: ustekinumab, oral and rectal mesalamine | Crohn’s disease: ustekinumab | Ulcerative colitis: oral mesalamine |
Conclusion
In this large prospective cohort of children born to mothers with IBD, vaccination, including live-attenuated vaccines, showed a favourable safety profile after maternal biologic exposure during pregnancy or breastfeeding. These real-world data support routine infant vaccination and may help reduce unnecessary delays, particularly for live vaccines.
References
1. Esposito S, Antoniol G, Labate M, et al. Vaccines in children with inflammatory bowel disease: Brief review. Vaccines. 2021;9(5).
2. Benchimol EI, Tse F, Carroll MW, et al. Canadian Association of Gastroenterology Clinical Practice Guideline for Immunizations in Patients With Inflammatory Bowel Disease (IBD)—Part 1: Live Vaccines. Gastroenterology. 2021;161(2):669-680.e0.
3. Torres J, Chaparro M, Julsgaard M, et al. European Crohn’s and Colitis Guidelines on Sexuality, Fertility, Pregnancy, and Lactation. J Crohn’s Colitis. 2023;17(1):1-27.
4. European Medicines Agency (EMA). Direct healthcare professional communication (DHPC). Infliximab (Remicade, Flixabi, Inflectra, Remsima and Zessly): Use of live vaccines in infants exposed in utero or during breastfeeding.
5. European Medicines Agency (EMA). ICH E2A - Clinical Safety Data Managements: Definitions and Standards for Expedited Reporting. Drug News. 2010;23(1):71.
Disclosure
Marta Velasco Rodríguez-Belvís has served as speaker or education funding from Abbvie, Janssen, Abbott, Nestlé Health Science, Fresenius, Mead Johnson, Recordati, Adacyte Therapeutics, Nutricia.
Laura Palomino has received financial support for traveling and educational activities, or served as speaker for Adacyte, AbbVie, Casen Recordati, Norgine, Nestlé, Mead Johnson, Ordesa, Nutricia and Abbott.
Cristina Calviño-Suárez reports financial relationships with MSD, AbbVie, Janssen, Takeda, Adacyte, Pfizer, and Lilly, including speaker honoraria and/or support for travel and educational activities.
Marta Calvo Moya has served as speaker, consultant, and advisory member for or has received research funding from MSD, Abbvie, Pfizer, Kern Pharma, Mylan, Takeda, Johnson & Johnson, Gilead/Galapagos/Alfasigma, Lilly, Ferring, Faes Farma, Shire Pharmaceuticals, Dr. Falk Pharma, Tillotts Pharma and Chiesi.
Mariam Aguas has served as speaker, consultant or research or education funding from Abbvie, Adacyte, Alfasigma, Chiesi, Faes Farma, Ferring, Johnson & Johnson, Kern Pharma, Lilly, Norgine y Pfizer.
Agnès Fernández-Clotet has served as a speaker, or has received educational funding from Dr. Falk, Janssen, Takeda, Chiesi, Lilly, Abbvie and Pfizer.
Raquel Vicente Lidón has served as speaker, consultant, advisory member for or has received education funding from MSD, Abbvie, Pfizer,Takeda, Janssen/Johnson & Johnson, Galapagos/Alfasigma, Lilly, Ferring, Faes Farma, Shire Pharmaceuticals, Dr. Falk Pharma, Tillotts Pharma and Chiesi.
Montserrat Rivero has served as a speaker or advisory member from Lilly, TaKeda, Janssen, Abbvie, Galapagos, Ferring and Pfizer.
Jose María Huguet has served as speaker, consultant or research or education funding from MSD, Ferring, Abbvie, Johnson & Johnson, Biogen, Sandoz, Kern Pharma, Faes Farma, Lilly, Tillots and Takeda.
Pilar López Serrano has received research funding, travel grants, or speaker fees from AbbVie, Dr. Falk Pharma, FAES, Falk Foundation, Ferring, MSD, and Johnson and Johnson.
Iago Rodríguez-Lago has received financial support for traveling and educational activities from or has served as an advisory board member for Abbvie, Adacyte, Alfasigma, Biogen, Faes Farma, Ferring, Galapagos, Johnson&Johnson, Eli Lilly, Mirum Pharmaceuticals, Merck, Pfizer, Roche, Takeda, and Tillotts Pharma. Research support from AbbVie and Alfasigma.
Marta Maia Bosca-Watts has served as speaker, consultant, and advisory member for or has received research funding from MSD, Ferrin g, Abbvie, Janssen, Biogen, Pfizer, Galápagos, Otsuka, Kernpharma and Takeda.
David Busquets has served as speaker or education funding from Abbvie, Johnson & Johnson, Lilly, Kern Pharma, Takeda, Pfizer, Tillots Pharma.
Míriam Mañosa has served as speaker, consultant or research or education funding from MSD, Abbvie, Pfizer, Takeda, Janssen, Ferring, Kern Pharma, Dr. Falk Pharma, Tillotts Pharma, and Lilly.
María Chaparro has served as speaker, consultant or research or education funding from MSD, Abbvie, Hospira, Pfizer, Takeda, Janssen, Ferring, Shire Pharmaceuticals, Dr. Falk Pharma, Tillotts Pharma, Biogen, Gilead and Lilly.
JP Gisbert has served as speaker, consultant, and advisory member for or has received research funding from MSD, Abbvie, Pfizer, Kern Pharma, Biogen, Mylan, Takeda, Janssen, Roche, Sandoz, Celgene/Bristol Myers, Gilead/Galapagos/Alfasigma, Lilly, Sanofi, STADA, AMGEN, Teva, Ferring, Faes Farma, Shire Pharmaceuticals, Dr. Falk Pharma, Tillotts Pharma, Chiesi, Casen Fleet, Gebro Pharma, Otsuka Pharmaceutical, Norgine, Italfarmaco, and Vifor Pharma.
The remaining authors declare no conflicts of interest.